(XBI) S&P Biotech - Overview
Exchange: NYSE ARCA •
Country: USA •
Currency: USD •
Type: Etf •
ISIN: US78464A8707
Etf: Biotech, Mid-Cap, Equal, Equities
Total Rating 76
Risk 56
Buy Signal -0.09
| Risk 5d forecast | |
|---|---|
| Volatility | 26.0% |
| Relative Tail Risk | 2.43% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.39 |
| Alpha | 29.49 |
| Character TTM | |
|---|---|
| Beta | 1.001 |
| Beta Downside | 1.249 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.99% |
| CAGR/Max DD | 0.49 |
Description: XBI S&P Biotech March 02, 2026
The SPDR® S&P Biotech ETF (XBI) aims to replicate the S&P Biotechnology Select Industry Index by using a sampling approach, allocating at least 80% of its assets to the index’s constituents, which represent the biotech segment of the broader S&P Total Market Index.
As of the latest data, XBI carries a low expense ratio of 0.35%, manages roughly $2.1 billion in assets, and posted a year-to-date return of about 12% driven by strong FDA approval pipelines and robust R&D spending in the sector. Recent macro trends, such as easing interest rates and heightened investor appetite for innovative therapeutics, continue to bolster biotech valuations.
For deeper insights, you might explore ValueRay’s analytical tools to complement your research.
Altman Z''
Beneish M
| DSRI: none (Receivables none/none, Revenue 0.0/0.0) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: none (Revenue 0.0 / 0.0) |
| TATA: none (NI 0.0 - CFO 0.0) / TA none) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of XBI shares?
As of March 05, 2026, the stock is trading at USD 126.42 with a total of 8,449,627 shares traded.
Over the past week, the price has changed by -1.45%, over one month by +0.90%, over three months by +2.91% and over the past year by +47.33%.
Over the past week, the price has changed by -1.45%, over one month by +0.90%, over three months by +2.91% and over the past year by +47.33%.
Is XBI a buy, sell or hold?
S&P Biotech has no consensus analysts rating.
What are the forecasts/targets for the XBI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
XBI Fundamental Data Overview February 28, 2026
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 8.44b USD (8.44b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 8.44b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 8.44b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.60% (E(8.44b)/V(8.44b) * Re(9.60%) + (debt-free company))
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
[DCF] Fair Price = unknown (Cash Flow 0.0)
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 8.44b USD (8.44b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 8.44b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 8.44b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.60% (E(8.44b)/V(8.44b) * Re(9.60%) + (debt-free company))
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
[DCF] Fair Price = unknown (Cash Flow 0.0)